Title: Physiological foundation modeling for subclinical disease assessment: a

prospective pilot

Authors: Yuan, William, PhD[1]; Xu, Shiwei, PhD[1]; Dionisi, Sara, PhD[2]; von Herrmann,

Katharine, PhD[1,2]; Frederick-Dyer, Kate, MD[3]; Cheung-Flynn, Joyce, PhD[4]; Kennedy, Caleb,

PhD[1*]; Flynn, Charles R, PhD[5*]; Lipnick, Scott, PhD[1,2*]

*co-senior author

Affiliations: 1) Etiome Inc, Cambridge, MA; 2) Flagship Pioneering, Cambridge, MA; 3)

Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center,

Nashville, TN, USA, 4) Department of Vascular Surgery, Vanderbilt University Medical Center,

Nashville, TN, USA, 5) Department of Surgery, Vanderbilt University Medical Center, Nashville,

TN, USA

Author Contributions:

CK had full access to all of the data in the study and takes responsibility for the integrity of the

data and the accuracy of the data analysis.

Conceptualization: W.Y., S.L., R.F., C.K.; **Methodology:** W.Y., S.X.; **Software:** W.Y., S.X.;

Validation: W.Y., S.X.; **Investigation:** W.Y., S.X., S.D., K.F.-D., J.C.-F., R.F.; **Resources:** W.Y.,

J.C.-F., R.F.; **Data Curation:** W.Y., S.X., J.C.-F., R.F.; **Writing:** all authors; **Supervision:** S.L.,

R.F., C.K.; **Administration:** S.L., R.F., C.K.

COI Disclosures: W.Y, S.X, and C.K are employees of Etiome Inc. S.D, K.VH, and S.L are

employees of Flagship Pioneering. C.R.F, J.C.-F, and K.F.-D are employed by Vanderbilt

University Medical Center.

Funding and Support: This study was funded in full by Etiome Inc.

Keywords: liver steatosis, patient representations, clinical trials

Data Sharing Statement: The UK Biobank is available for use at https://www.ukbiobank.ac.uk

by submitting a data request. The specific data from these studies used in this current work

were used under license and so are not available. NHANES is freely available for use at

https://www.cdc.gov/nchs/nhanes/index.html. The data from the Gifu, Kaohsiung, and Iksan

cohorts are freely available at their respective journals. The Dandelion cohort was used under

license and so is not available. The ReMasker algorithm is freely available at

https://github.com/alps-lab/remasker. The CARD algorithm is implemented in the freely

available Lightning-UQ-Box package (https://pypi.org/project/lightning-uq-box/). The remaining

data and analytic methods used in this study will remain the confidential property of the study

sponsors. Data may be made available to other researchers upon request following permission,

investigator support and following a signed data access agreement.

Word Count: 3341

Abbreviations: MASLD, metabolic dysfunction-associated steatotic liver disease; PDFF,

proton density fat fraction.

Corresponding Author: William Yuan; wyuan@etiome.bio

Abstract (246):

Objective: Clinical studies struggle to locate the right patients, in part because many remain

undiagnosed or lack relevant labels. We develop and prospectively test a physiology-based

patient representation ('Bioprofile') to evaluate whether it can reduce the number of individuals

who must be screened and enable more precise targeting of candidates for steatotic liver

disease studies.

Materials and Methods: We trained Bioprofile patient representations from routinely collected

health data and fine-tuned against multiple endpoints. Bioprofiles were trained using 1 million

subjects from the UK Biobank and other cohorts. The trained model was applied to 45,484

research subjects at Vanderbilt University Medical Center. Based on Bioprofile nominations, 31

subjects were recruited for a prospective validation study. The primary outcome measure was

proton density fat fraction (PDFF), an imaging-based metric of steatosis severity.

Results: Bioprofile models achieved a Spearman coefficient of 0.65 against PDFF,

outperforming existing foundation models (ρ = 0.361) and clinical risk scores (ρ = 0.522-0.542)

in retrospective validation. Simulations found that Bioprofiles required half as many subjects

needed to screen compared to existing methods depending on task. Bioprofiles were further

validated against 3 global cohort studies. Bioprofile predictions aligned strongly with prospective

study data (ρ = 0.740).

Discussion and Conclusion: AI-based profiling of patient physiology can reveal individuals who

have subclinical signatures of disease. If implemented widely, this approach can identify

unknown human subjects, reduce screening failures, and improve trial quality. Bioprofiles may

have additional utility in decision support applications in precision medicine and AI-augmented

healthcare.

Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD; formerly non-alcoholic fatty

liver disease, NAFLD[1]) is highly prevalent yet remains markedly underdiagnosed in clinical

practice[2]. The condition, defined by liver fat accumulation (hepatic steatosis) in the presence of

metabolic risk factors, affects over a quarter of adults worldwide[3]. However, many individuals

with MASLD are never diagnosed, owing to its often subclinical course and the limited use of

definitive diagnostics in routine care[4–6]. This poses a major challenge for patient recruitment in

clinical studies, as potentially eligible participants may be missed. Even when MASLD is

suspected, confirming steatosis severity typically requires imaging or biopsy, introducing

logistical or financial hurdles in human trials[7,8]. MRI-based proton density fat fraction (PDFF)

measurements are considered a gold-standard for noninvasive quantification of liver fat and are

commonly used as an inclusion criterion for clinical trials. Changes in PDFF are also used as an

endpoint of treatment efficacy for steatosis reduction[9–11] However, MRI is expensive, time-

intensive, and not accessible at scale[12,13,14].

There is a clear need for steatosis metrics that are both non-invasive and scalable to flag high-

risk patients. Simple clinical scores[15,16] estimate MASLD probability from routine labs and

demographics but offer only moderate accuracy that is insufficient to precisely quantify liver fat

or guide trial enrollment. One recent study[17] developed an artificial intelligence (AI) algorithm for

identifying subjects based on electronic health records (EHRs) at particularly high risk and

hypothesized that such an algorithm could support earlier screening and even facilitate

recruitment for trials. However, this algorithm was only externally validated on retrospective real-

world data where true disease labels were unavailable. Furthermore, human studies, particularly

those focused on discovery efforts, may aim to identify subjects at various stages of disease,

rather than just one. More broadly, foundation models, which utilize broad pre-training to enable

prediction of multiple down-stream endpoints, have been applied to a wide set of healthcare

applications, but liver specific applications and real-world validation have not been performed to

our knowledge[18].

In this work, we introduce and validate Bioprofiles, a foundation model of human physiology

trained on large, diverse cohorts, first applied in a cardiometabolic context to detect patterns

linked to liver-fat accumulation. By integrating clinically accessible data (demographics, medical

history, laboratory results, and lifestyle factors), Bioprofiles can estimate an individual's liver fat

distribution without additional tests or imaging. Bioprofiles offer a non-invasive, easy-to-use tool

to nominate likely MASLD patients before any intervention or imaging is done, thereby

broadening the pool of trial-eligible participants. Outside of a trial setting, steatosis identification

can contribute to qualifying patients for glucagon like peptide 1 receptor agonists (GLP1

RAs)[19],enabling earlier therapeutic engagement. In this manuscript, we evaluate Bioprofiles in a

prospective pilot for MASLD trial recruitment.

Methods

Data sources

Deidentified data from participants in the UK Biobank[20] (n = 500k), NHANES[21] (n = 90k) and an

internal set of hospital-based cohort data (n = 460k) were included in this study. The UK

Biobank was subdivided into pretraining (n = 450k) and fine-tuning (n = 43k) sets based on

availability of liver imaging data. Summary statistics from a set of 45,484 subjects from

Vanderbilt University Medical Center (VUMC) were also utilized for calibration.

Step 1: Model training

The primary endpoint considered was PDFF, measured using magnetic resonance imaging

(MRI), which measures the relative degree of contributing signal from fat versus water and is

expressed as a percentage value[22]. Clinically-accessible data elements including

demographics, medical history, lab results, and lifestyle factors were extracted and manually

harmonized across datasets. Factors were chosen based on what would plausibly be available

or accessible during a primary care encounter. ReMasker[23], a masked autoencoder originally

designed for tabular imputation, was used to generate patient-level embeddings

(Supplementary Methods, Supplementary Figure 3). Because PDFF is known to exhibit

heteroscedasticity[24] we utilized CARD,[25] a method utilizing diffusion models for tabular

regression and classification tasks that generates fuller conditional distributions of predicted

PDFF, rather than just an estimate of mean and variance, enabling more sensitive estimates of

predictive uncertainty. The CARD implementation from lightning-uq-box 0.2.0 was used.

Hyperparameters for both ReMasker and CARD were optimized using Optuna 3.0.4

(Supplementary Table 6-7). All model building was performed using Torch 2.6.0 and Python 3.10

using an NVIDIA A10G GPU (Supplementary Figure 1A). The fine-tuning set was itself split into

non-overlapping training, test, and validation sets (65:10:25). To ensure model performance was

properly evaluated over the full spectrum of PDFF, we resampled the test set to a uniform

distribution over PDFF bins.

To benchmark performance, we compared Bioprofile predictions to those generated by CLMBR,

a recent foundation model that utilizes longitudinal electronic health records[26,27], the

Framingham Steatosis Index (FSI)[15], and Hepatic Steatosis Index (HSI)[16]. We also employed

two technical benchmarks: a gradient boosted regressor trained over the fine-tuning set, with

access to i) body mass index (BMI), alanine aminotransferase (ALT), and aspartate

aminotransferase (AST) levels, and ii) all Bioprofile input features. Bioprofile performance was

also evaluated relative to the full technical benchmark on a series of non-proton density fat

fraction (PDFF) tasks (Supplementary Table 1).

Step 2: Targeted recruitment task:

The first recruitment task we considered was to identify subjects with PDFF > 10%. This

corresponds to a common inclusion criterion for interventional trials, where sponsors are

interested in ensuring that recruited subjects have a sufficient amount of steatosis[28,29]. In

simulated studies and during the VUMC recruitment pilot, we aimed to minimize the number of

subjects screened to recruit 12 subjects with PDFF > 10%. The specific recruitment targets for

the study were derived from sample size (Supplement) and logistical study considerations.

Step 3: Even recruitment task:

The second recruitment task we considered was to identify a uniform number of subjects across

PDFF, specifically PDFF between 0% and 5%, between 5% and 15%, and above 15%,

corresponding to healthy, mild, and moderate degrees of steatosis[30]. These correspond to a

discovery-related task where a sponsor is interested in obtaining a sufficient number of subjects

across a transition between relative health and disease, for the purpose of developing or

validating a diagnostic or biomarker[31]. In simulated studies and during the VUMC recruitment

pilot, we aimed to minimize the number of subjects screened to recruit at least 9 subjects across

all 3 bins.

Step 4: Cohort nomination algorithm

We developed an algorithm (Portfolio Selection, Supplementary Figure 1B) to nominate subjects

for recruitment based on CARD-generated conditional probability distributions over predicted

PDFF. We utilized linear programming to nominate subcohorts of subjects that minimized the

Wasserstein distance between i) the collective conditional PDFF distribution of the nominated

subcohort and ii) the goal distribution (all subjects with PDFF > 10% or even distribution of

PDFF over 3 bins). Nominated subjects would be recruited and measured, and a new goal

distribution defined if needed. Constraints such as recruitment batch size, latency between

cohort identification, and measurement were simulated. Notably, for the VUMC study, we were

able to embed the targeted recruitment task within the even recruitment task, identifying a single

recruitment policy that simultaneously met both criteria (Supplementary Figure 1C). The

Portfolio Selection algorithm is described in the Supplement and was trained using PuLP 2.7.0

and the PULP_CBC_CMD solver.

Step 5: Study recruitment simulations

To evaluate the difficulty of obtaining cohorts with desired distributions, we simulated the ability

of various models to guide subject recruitment studies across both tasks (targeted and even

recruitment). These experiments were performed using the test set without label resampling.

Furthermore, we evaluated two methods for model-guided subject recruitment: standard

sampling, and Portfolio Selection. For standard sampling in targeted recruitment, subjects were

recruited in rank order based on their model-assessed probability of having PDFF > 10%. For

standard sampling in even recruitment, subjects were recruited in batches of 5 based on rank

order of model-assessed probability of membership in each of the three bins, with recruitment

shifting across bins as recruitment goals are reached (adaptive sampling).

Subject screening and pre-recruitment

To operationalize the model-guided recruitment, we first utilized the Bioprofile and Portfolio

Optimization algorithms to define a recruitment policy that would minimize the number of

required recruits to achieve the goal distribution. This policy consisted of a set of several model-

defined subpopulations to be recruited in a certain ratio. We used knowledge distillation with

Bioprofile/Portfolio Optimization labels (teacher) to train a set of logistic regression classifiers

(student) that were deployed at VUMC. We found that the student model had comparable

performance to the teacher in terms of projected study performance (Supplementary Table 4).

VUMC health records in the Epic data warehouse were eligible if they were between the ages of

21 and 70. Exclusion criteria for the fine-tuning cohort and VUMC recruitment cohort included

pregnancy or breast-feeding, presence of implanted cardiac defibrillator or pacemaker,

presence of cancer and/or ongoing cancer treatment, presence of HIV, history of alcohol

consumption exceeding 14 drinks per week for men and greater than seven per week for

women, illicit drug use, treatment with any investigational drug in the one month preceding

study, mental conditions rendering an inability to understand the nature, scope and possible

consequences of the study, inability to comply with the protocol (Supplementary Information).

We also excluded subjects with existing diagnoses of MASLD from the VUMC recruitment

cohort to evaluate the utility of our models on identifying undiagnosed MASLD. The study was

approved by the Vanderbilt IRB (230833).

Subject recruitment and sampling

A recruitment cohort of 45,484 subjects was identified in the VUMC clinical data warehouse

based on inclusion, exclusion, data density, and subject accessibility requirements

(Supplementary Information). Bioprofile student models were deployed on data present in their

medical record (Pre-visit EHR Extract) and used to nominate subjects for recruitment, but a full

physical exam and lab series was performed at the study visit (Study Visit). Data on all cohorts

are provided in Table 1. After the study visit, Bioprofile teacher models were deployed on

deidentified pre-visit and study visit data. A CONSORT diagram of participant recruitment is

provided in Supplementary Figure 2. Participants were compensated for their participation in the

study. No adverse reactions were reported as part of participation.

	Pretraining Cohort (1M)		UKB Imaging Cohort (n=43k)			VUMC Cohort (Pre-Visit EHR Extract) (n=29) (2 ineligible for MRI)			VUMC Cohort (Study Visit) (n=29) (2 ineligible for MRI)		
	Metric	Fraction with Data	PDFF < 5% (32k)	5% < PDFF < 15% (9.1k)	PDFF > 15% (2.1k)	PDFF < 5% (10)	5% < PDFF < 15% (9)	PDFF > 15% (9)	PDFF < 5% (11)	5% < PDFF < 15% (9)	PDFF > 15% (9)
Age (years)	49.61 (49.58 - 49.63)	1	55.01 (54.93 - 55.09)	55.47 (55.32 - 55.63)	54.1 (53.85 - 54.42)	50.06 (40.42 - 58.54)	41.45 (33.63 - 48.51)	43.28 (37.77 - 49.12)	50.55 (40.18 - 60)	41.49 (34.5 - 50.13)	43.55 (36.19 - 50.23)
Sex (fraction male)	0.486 (0.485 - 0.487)	1	0.439 (0.434 - 0.443)	0.606 (0.597 - 0.616)	0.576 (0.556 - 0.597)	0.618 (0.25 - 0.875)	0.533 (0.163 - 0.777)	0.644 (0.333 - 0.888)	0.618 (0.25 - 0.875)	0.533 (0.163 - 0.777)	0.644 (0.333 - 0.888)
BMI (kg/m2)	25.29 (25.28 - 25.3)	0.992	25.65 (25.61 - 25.69)	28.84 (28.76 - 28.93)	30.53 (30.36 - 30.77)	23.39 (21.57 - 26.34)	38.29 (33.91 - 43.88)	36.42 (32.78 - 40.98)	23.52 (21.12 - 26.31)	37.14 (32.41 - 41.44)	37.47 (33.05 - 40.95)
Triglycerides	1.55 (1.54 -	0.955	1.47 (1.46 -	2.04 (2.07 -	2.29 (2.24 -	0.683 (0.484	1.48 (1.27 -	2.67 (1.69 -	0.698 (0.52 -	1.47 (1.28 -	2.94 (2.1 -

	1.55)		1.48)	2.12)	2.35)	- 0.88)	1.67)	3.92)	0.863)	1.69)	3.81)
Serum ALT (U/L)	23.11 (23.08 - 23.14)	0.923	20.7 (20.58 - 20.83)	28.12 (27.86 - 28.41)	35.68 (34.82 - 36.79)	21.69 (15.93 - 28.32)	49.16 (27.22 - 73.63)	71.81 (47.68 - 96.06)	21.66 (15.61 - 26.57)	48.37 (27.39 - 74.78)	78.8 (56.93 - 101.7)
Serum AST (U/L)	24.95 (24.93 - 24.98)	0.801	25 (24.91 - 25.13)	27.41 (27.16 - 27.67)	30.6 (30.1 - 31.16)	27.27 (21.18 - 34.45)	31.86 (24.94 - 42.19)	42.29 (30.15 - 54.65)	27.56 (21.93 - 33.32)	31.53 (25.05 - 39.51)	47.08 (33.88 - 64.11)
Diabetes Status	0.043 (0.043 - 0.044)	0.767	0.0168 (0.0154 - 0.0182)	0.0511 (0.0475 - 0.0561)	0.0704 (0.060 - 0.082)	0 (0 - 0)	0.57 (0.222 - 0.888)	0.755 (0.444 - 1)	0 (0 - 0)	0.539 (0.222 - 0.836)	0.793 (0.555 - 1)
PDFF	N/A	0	2.60 (2.59 - 2.61)	8.36 (8.31 - 8.41)	21.0 (20.7 - 21.2)	N/A	N/A	N/A	2.10 (1.73 - 2.46)	9.90 (7.59 - 11.7)	30.1 (24.9 - 35.0)

Table 1: Characteristics of the pretraining, fine-tuning, and recruited cohorts. All values are means (95% confidence interval) unless otherwise indicated.

The MyHealth@Vanderbilt platform was used to consent and engage nominated subjects. Recruited subjects were invited to participate in a study visit consisting of body measurements, venipuncture, blood analyses, and liver magnetic resonance imaging with the purpose of measuring PDFF.

Subject schedule of study events

31 subjects who met inclusion and exclusion criteria were invited to the Vanderbilt Clinical Research Center after an overnight fast. A brief physical examination including measures of waist, hip, and chest circumference along with blood pressure were taken prior to a blood draw for a lipid panel, CBC, CMP and measurement of HbA1c. 2 subjects were found to be incompatible with MRI screening during the study visit. 29 subjects underwent MRI evaluation of the upper abdomen using the mDixon protocol. Results of estimated percentage of liver fat by MR method and Bioprofile-predicted liver fat content were correlated.

MRI examination of liver was done with a 3T MR7700 MR system (Philips Healthcare,

Netherlands) with a quadrature body transmit coil used in combination with a 32-channel

anterior receive coil array and 16-channel posterior receive coil array. Anatomic imaging of

entire upper abdomen was performed with axial, free-breathing single-shot Turbo Spin Echo

(TSE) sequence. A commercially available version of mDIXON sequence package was used to

acquire fat and water images of entire liver. Following were the mDIXON Quant imaging

parameters: 3D T1-FFE sequence, FOR=400/350/231mm, acq. vox.dim.=3/3/6mm (over

contiguous slices with 3mm overlap), 6-echoes: TE1/delta_TE=0.92/0.7 msec, TR=5.2 msec,

Flip angle=3deg, SENSE =1.5,1.5 in two directions. Breath-hold duration was 13.5 seconds,

and a respiratory sensor was used to monitor compliance. The entire protocol lasted 15-20

minutes.

Data for each 2-echo mDIXON sequence was reconstructed on the MR system using the

available standard single-peak spectral model of fat. Each sequence yielded four images per

slice: water only, fat only, in-phase, out-phase. From the DICOM "water" and "fat" images, a

pixel-wise "signal fat-fraction" parameter map was generated as follows using an offline post-

processing tool. Fat percentage was calculated as (SI (Fat) x 100)/(SI(W+F)) where SI is the

pixel signal intensity on the reconstructed fat and water images. Images were independently

analyzed by a trained abdominal radiologist, documenting direct reading of percentage of fat in

all eight hepatic segments using an ROI of 200-300 mm. Care was taken to select only

representative regions, avoiding hepatic vasculature, biliary structures, or regions with artifacts.

Results

Bioprofiles accurately predict MRI-assessed liver fat infiltration

Alignment of model predictions with PDFF was assessed across 3 metrics: AUROC at 5%, 15%,

and Spearman coefficient. In the validation set, Bioprofiles outperformed foundation model

(CLMBR[26,27]), clinical (FSI[15], HSI[16]), and technical benchmarks on all tasks (Table 2). Notably,

CLMBR underperformed steatosis-specific clinical benchmarks at estimating PDFF.

	AUC (PDFF= 5%)	AUC (PDFF= 15%)	Spearman Correlation vs. PDFF
CLMBR (EHR-based Foundation Model)	0.693 (0.681-0.705)	0.716 (0.690-0.741)	0.361 (0.345-0.377)
Framingham Steatosis Index (FSI)	0.773 (0.744-0.802)	0.751 (0.717-0.785)	0.522 (0.472-0.566)
Hepatic Steatosis Index (HSI)	0.793 (0.766-0.821)	0.743 (0.709-0.777)	0.542 (0.495-0.584)
Gradient Boosted (BMI/ALT/AST)	0.800 (0.774-0.827)	0.760 (0.727-0.794)	0.569 (0.522-0.612
Gradient Boosted (All Bioprofile input features)	0.827 (0.802-0.852)	0.772 (0.739-0.805)	0.604 (0.559-0.643)
Bioprofile	**0.851 (0.828-0.874)**	**0.801 (0.770-0.833)**	**0.650 (0.608-0.687)**

Table 2: Model performance for predicting PDFF. All values are means (95% confidence

interval) unless otherwise indicated.

To account for patterns of gaps in real-world data, we conducted sensitivity testing over data

availability. We synthetically masked the fine-tuning cohort based on feature availability patterns

learned from an external real-world EHR dataset to evaluate all models (Supplementary Table

2). Under these conditions, the Bioprofiles continued to outperform all benchmarks on all tasks.

To evaluate the generalizability of our models, we evaluated data from 5 clinical trials and

hospital-based cohort studies where steatosis or MASLD status was assessed[32–36]. Bioprofiles

continued to outperform clinical and technical benchmarks in all cases. (Table 3)

	Framingham Steatosis Index (FSI)	Hepatic Steatosis Index (HSI)	Gradient Boosted (All Bioprofile input features)	Bioprofile

Gifu Cohort[34] (AUROC vs ultrasound assessed MASLD status) (n=786)	0.86 (0.83-0.89)	0.84 (0.8-0.88)	0.85 (0.82-0.89)	**0.88 (0.85-0.91)**
Kaohsiung Cohort[35] (AUROC vs ultrasound assessed MASLD severity) (n=407)	0.69 (0.64-0.75)	0.68 (0.63-0.74)	0.68 (0.63-0.74)	**0.74 (0.69-0.78)**
Iksan Cohort[36] (Spearman R vs. CT-assessed disease severity) (n=913)	0.25 (0.18-0.31)	0.36 (0.29-0.42)	0.35 (0.29-0.41)	**0.43 (0.37-0.49)**

Table 3: External model validation on fatty liver status/biopsy (LBX)-confirmed steatosis. All values are means (95% confidence interval) unless otherwise indicated.

Bioprofiles facilitate efficient subject nomination in simulation

To understand the impact of model improvements on study logistics, we conducted study simulations on each of our validation sets. For most model/task combinations, Portfolio Selection tended to outperform standard sampling, and Bioprofiles outperformed clinical benchmarks. However, for the targeted recruitment task, Bioprofiles alone were sufficient to achieve strong performance, likely due to the simpler desired distribution (Supplementary Tables 3, 4). However, on the even recruitment task, we observed a synergistic effect between the use of Bioprofile patient representations and the Portfolio Selection algorithm. To identify 12 subjects with PDFF > 10%, the Bioprofile required 19 screened subjects compared to 39 (HSI) and 43 (FSI). To identify 27 subjects in the even recruitment task, Bioprofiles required only 30 subjects screened, compared to 60 subjects (HSI) and 69 subjects (FSI) (Table 4). Notably, Bioprofile performance for the even recruitment task is close to ideal, with only three additional screenings projected to achieve recruitment goals. Study performance and variance for the even recruitment task was found to be a function of recruitment pool size (Supplementary Table 5).

	Targeted Recruitment (12 with PDFF > 10%)		Even Recruitment (9 each with i) 0% ≤ PDFF < 5%, ii) 5% ≤ PDFF ≤ 15%, iii) 15% ≤ PDFF)	
Random Sampling	116 (98-143)		161 (127-217)	
	Standard Sampling	Portfolio Selection	Standard Sampling	Portfolio Selection
FSI	43 (40-44)	37 (36-38)	69 (67-71)	50 (49-51)
HSI	39 (36-41)	34 (33-35)	60 (58-62)	47 (46-47)
Bioprofile	**19 (16-22)**	**19 (19-20)**	44 (43-45)	**30 (30-30)**

Table 4: Simulated Recruitment Requirements for the fine-tuning set. All values are means (95%

confidence interval) unless otherwise indicated.

Bioprofiles successfully nominated of subjects for a human study

Using our Portfolio Selection algorithm, we identified a recruitment strategy that would enable us

to embed the targeted recruitment task within the even recruitment task with minimal projected

impact on total recruitment numbers (Supplementary Figure 1C). Recruitment was therefore

conducted in two waves: first, the subpopulation collectively projected to have PDFF > 10% was

recruited, followed by the subpopulations needed to obtain even recruitment. We deployed the

student model over 45,484 individuals who met inclusion criteria in the VUMC CDW, and over 3

months of outreach, contacted 1,388 individuals through the MHAV platform. The targeted

recruitment task was achieved after 20 subjects were screened, and the even recruitment task

after 9 additional subjects, for 29 total screens. These values are in line with study simulations

(Table 4) and result in substantially reduced numbers of excess screens relative to existing

standards (Figure 1A, B). Next, we examined Bioprofile teacher model performance using

deidentified pre-study and study visit data. We examined continuous measures of liver fat

abundance, independent of bin definitions, comparing the Bioprofile predicted PDFF distribution

to i) expected background and ii) actual observed distributions (Figure 1C). The predicted

distribution was found to be significantly different from the background (KS test: p < 1E-3) but

not significantly different to the distribution observed in enrolled study participants (KS test: p =

0.6). Finally, teacher Bioprofiles maintained strong subject level performance for PDFF among

the recruited subjects (Figure 1D).

Discussion

Our study demonstrates that AI-driven patient profiling can meaningfully surface subclinical

disease signatures hidden in routine clinical data, providing a basis for streamlining clinical trial

recruitment and enabling more proactive patient care. Using Bioprofiles, we efficiently

nominated candidate participants for a prospective pilot study at VUMC, achieving high yield

and strong agreement with imaging findings. By leveraging routine health record data pre-

emptively, our approach enabled targeted invitations to patients who were most likely to qualify,

thereby reducing screening failures. Simulation studies showed that the Bioprofile nomination

pipeline halved the number of subjects that had to be screened to enroll the same number of

eligible participants compared with conventional risk scores or untargeted approaches.

The relatively poor performance of an EHR-based foundation model on the PDFF prediction

task highlights one of the intrinsic limitations of real-world data sources. Because the features

captured in the EHR are typically generated through expressions of clinical judgement[37], they do

not provide complete representation of patient physiology. For diseases associated with

substantial rates of underdiagnosis or clinical uncertainty, our approach of directly modeling

accessible physiology is more likely to capture relevant disease states.

From a broader perspective, this work illustrates how a foundation model of cardiometabolic

health can be translated into tangible recruitment benefits. While our study focused on trial

recruitment, the underlying approach, estimating the results of less accessible tests using more

accessible features, has much wider potential applications. Most immediately, Bioprofile patient

representations have potential for providing probabilistic estimates for a wide series of

cardiometabolic endpoints. Bioprofile-generated probability distributions can be easily

incorporated into health economic or net-benefit calculations with the goal of optimizing care

delivery and resource allocation. More directly, by mapping the overlap between Bioprofile

output and existing clinical practice guidelines, Bioprofiles could act as a source of risk

stratification or decision support.

Our findings should be interpreted in light of certain limitations. Our external validation focused

on populations from Asia and trial participants. We are currently planning more extended

validation in American community health contexts. Our VUMC pilot included 29 screens, which,

while sufficient to demonstrate feasibility, is a small sample to fully establish the model's

performance characteristics. These subjects were also model-selected based on likelihood of

meeting inclusion criteria and subject to response bias and so are not necessarily

representative of the wider population. Our aggressive approach to feature mapping and

curation was helpful in driving signal but was also highly labor intensive. Methods for interfacing

or computing Bioprofiles from standard data models will be needed to enable wider-scale

deployment. Finally, as currently configured, Bioprofiles are best suited to the highest

prevalence indications among seemingly healthy primary care encounters. While we believe

they can be extended to other indications, alternative datasets will be necessary to capture the

full slate of "clinically accessible data" in other contexts.

In summary, this pilot highlights a promising future where AI-based physiological profiling

becomes a routine tool for improving research efficiency and patient care. By leveraging routine

health data to surface individuals with subclinical or unlabeled disease, Bioprofile modeling

enabled precise and efficient recruitment in a MASLD-focused study, reducing the screening

burden and improving alignment with inclusion criteria. This approach has the potential to

accelerate drug development (through faster, more cost-effective trials) and to improve patient

outcomes (through earlier detection and intervention). Beyond MASLD, applying Bioprofiles to

identify subclinical cases could transform trial logistics and clinical care across a broad range of

conditions by converting an invisible reservoir of patients into an actionable cohort for early

identification, recruitment or discovery.

Figure 1: Results of VUMC Bioprofile Deployment Pilot: A, B) Bar charts of included/excluded

subjects for targeted (A) and even (B) recruitment. Naïve sampling, clinical score and Bioprofile

projected represent simulations from Table 4. C) Kernel density estimates for the background

PDFF distribution (blue), Bioprofile predicted PDFF distribution (orange), and observed PDFF

distribution (green). D) Subject level model performance on VUMC-recruited cohorts, stratified

by input data type.

Bibliography

1. A multisociety Delphi consensus statement on new fatty liver disease nomenclature -
PubMed. Accessed May 13, 2025. https://pubmed.ncbi.nlm.nih.gov/37363821/

2. Nielsen EM, Anderson KP, Marsden J, Zhang J, Schreiner AD. Nonalcoholic Fatty Liver
Disease Underdiagnosis in Primary Care: What Are We Missing? *J Gen Intern Med*.
2022;37(10):2587-2590. doi:10.1007/s11606-021-07197-3

3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of
nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and
outcomes. *Hepatol Baltim Md*. 2016;64(1):73-84. doi:10.1002/hep.28431

4. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis
and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology
Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases
(AASLD) - PubMed. Accessed May 13, 2025. https://pubmed.ncbi.nlm.nih.gov/35569886/

5. Alexander M, Loomis AK, Fairburn-Beech J, et al. Real-world data reveal a diagnostic gap in
non-alcoholic fatty liver disease. *BMC Med*. 2018;16(1):130. doi:10.1186/s12916-018-1103-x

6. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic
fatty liver disease: Practice guidance from the American Association for the Study of Liver
Diseases. *Hepatol Baltim Md.* 2018;67(1):328-357. doi:10.1002/hep.29367

7. Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in
Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology.* 2019;156(5):1264-
1281.e4. doi:10.1053/j.gastro.2018.12.036

8. Harrison SA, Allen AM, Dubourg J, Noureddin M, Alkhouri N. Challenges and opportunities in
NASH drug development. *Nat Med.* 2023;29(3):562-573. doi:10.1038/s41591-023-02242-6

9. Stine JG, Munaganuru N, Barnard A, et al. Change in MRI-PDFF and Histologic Response in
Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. *Clin*
Gastroenterol Hepatol. 2021;19(11):2274-2283.e5. doi:10.1016/j.cgh.2020.08.061

10.   Flint A, Andersen G, Hockings P, et al. Randomised clinical trial: semaglutide versus
placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver
disease assessed by magnetic resonance imaging. *Aliment Pharmacol Ther.*
2021;54(9):1150-1161. doi:10.1111/apt.16608

11.   Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre,
randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet. Accessed May 13,
2025. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32517-
6/abstract?utm_source=chatgpt.com

12.   Idilman IS, Aniktar H, Idilman R, et al. Hepatic Steatosis: Quantification by Proton
Density Fat Fraction with MR Imaging versus Liver Biopsy. *Radiology.* 2013;267(3):767-775.
doi:10.1148/radiol.13121360

13.   Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and
their clinical importance in NAFLD. *Nat Rev Endocrinol.* 2022;18(1):55-66.
doi:10.1038/s41574-021-00584-0

14.   Davison BA, Harrison SA, Cotter G, et al. Suboptimal reliability of liver biopsy evaluation
has implications for randomized clinical trials. *J Hepatol.* 2020;73(6):1322-1332.
doi:10.1016/j.jhep.2020.06.025

15.   Long MT, Pedley A, Colantonio LD, et al. Development and Validation of the
Framingham Steatosis Index to Identify Persons with Hepatic Steatosis. *Clin Gastroenterol*
Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016;14(8):1172-1180.e2.
doi:10.1016/j.cgh.2016.03.034

16.   Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting
nonalcoholic fatty liver disease. *Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study*
Liver. 2010;42(7):503-508. doi:10.1016/j.dld.2009.08.002

17.   Schattenberg JM, Balp MM, Reinhart B, et al. NASHmap: clinical utility of a machine
learning model to identify patients at risk of NASH in real-world settings. *Sci Rep.*
2023;13(1):5573. doi:10.1038/s41598-023-32551-2

18.   He Y, Huang F, Jiang X, et al. Foundation Model for Advancing Healthcare: Challenges,
Opportunities and Future Directions. *IEEE Rev Biomed Eng*. 2025;18:172-191.
doi:10.1109/RBME.2024.3496744

19.   Novo Nordisk. Wegovy Insert ID 5342984.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf

20.   UK Biobank - UK Biobank. Accessed May 13, 2025. https://www.ukbiobank.ac.uk/

21.   CDC. National Health and Nutrition Examination Survey. National Health and Nutrition
Examination Survey. April 30, 2025. Accessed May 13, 2025.
https://www.cdc.gov/nchs/nhanes/index.html

22.   Starekova J, Hernando D, Pickhardt PJ, Reeder SB. Quantification of Liver Fat Content
with CT and MRI: State of the Art. *Radiology*. 2021;301(2):250-262.
doi:10.1148/radiol.2021204288

23.   Du T, Melis L, Wang T. ReMasker: Imputing Tabular Data with Masked Autoencoding.
arXiv. Preprint posted online September 25, 2023. doi:10.48550/arXiv.2309.13793

24.   Qadri S, Vartiainen E, Lahelma M, et al. Marked difference in liver fat measured by
histology vs. magnetic resonance-proton density fat fraction: A meta-analysis. *JHEP Rep*.
2023;6(1):100928. doi:10.1016/j.jhepr.2023.100928

25.   Han X, Zheng H, Zhou M. CARD: Classification and Regression Diffusion Models. *arXiv*.
Preprint posted online December 6, 2022. doi:10.48550/arXiv.2206.07275

26.   Steinberg E, Jung K, Fries JA, Corbin CK, Pfohl SR, Shah NH. Language models are an
effective representation learning technique for electronic health record data. *J Biomed Inform*.
2021;113:103637. doi:10.1016/j.jbi.2020.103637

27.   Wornow M, Thapa R, Steinberg E, Fries JA, Shah NH. EHRSHOT: An EHR Benchmark
for Few-Shot Evaluation of Foundation Models. *arXiv*. Preprint posted online December 11,
2023. doi:10.48550/arXiv.2307.02028

28.   Caussy C, Alquiraish MH, Nguyen P, et al. Optimal threshold of controlled attenuation
parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. *Hepatol
Baltim Md*. 2018;67(4):1348-1359. doi:10.1002/hep.29639

29.   Romero-Gómez M, Lawitz E, Shankar RR, et al. A phase IIa active-comparator-
controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-
alcoholic fatty liver disease. *J Hepatol*. 2023;79(4):888-897. doi:10.1016/j.jhep.2023.05.013

30.   Cunha GM, Thai TT, Hamilton G, et al. Accuracy of common proton density fat fraction
thresholds for magnitude- and complex-based chemical shift-encoded MRI for assessing
hepatic steatosis in patients with obesity. *Abdom Radiol N Y*. 2020;45(3):661-671.
doi:10.1007/s00261-019-02350-3

31.   Yuan W, Beaulieu-Jones BK, Yu KH, et al. Temporal bias in case-control design:
preventing reliable predictions of the future. *Nat Commun*. 2021;12:1107.
doi:10.1038/s41467-021-21390-2

32.   Tonascia J. Nonalcoholic Fatty Liver Disease Adult Database 2. Published online
December 3, 2024:8635907 B. doi:10.58020/EQRT-BX74

33.   Tonascia J. The Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment.
Published online January 13, 2023:10206968 MB. doi:10.58020/H3M1-Z998

34.   Fukuda T, Hamaguchi M, Kojima T, et al. Association between serum γ-
glutamyltranspeptidase and atherosclerosis: a population-based cross-sectional study. *BMJ
Open*. 2014;4(10):e005413. doi:10.1136/bmjopen-2014-005413

35.   Hsieh CJ, Wang PW, Hu TH. Association of Adiponectin Gene Polymorphism with
Nonalcoholic Fatty Liver Disease in Taiwanese Patients with Type 2 Diabetes. *PLoS ONE*.
2015;10(6):e0127521. doi:10.1371/journal.pone.0127521

36.   Han AL. Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-
alcoholic and alcoholic fatty liver disease: a retrospective analysis. *BMC Endocr Disord*.
2021;21(1):91. doi:10.1186/s12902-021-00758-x

37.   Beaulieu-Jones BK, Yuan W, Brat GA, et al. Machine learning for patient risk
stratification: standing on, or looking over, the shoulders of clinicians? *NPJ Digit Med*.
2021;4:62. doi:10.1038/s41746-021-00426-3

Acknowledgements